Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
Cancer Therapies02:49

Cancer Therapies

7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

148
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
148
Cancer Vaccines01:30

Cancer Vaccines

340
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
340

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Coffee, Tea, and Cognitive Function.

JAMA·2026
Same author

Case Report: Transverse myelitis following CAR-T cell therapy for post-transplant lymphoproliferative disorder.

Frontiers in immunology·2026
Same author

Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet. Oncology·2025
Same author

[Radiosurgery of benign intracranial lesions. Indications, results , and perspectives].

Revue medicale suisse·2025
Same author

Single-cell atlas of endothelial and mural cells across primary and metastatic brain tumors.

Immunity·2025
Same author

Initiating or Resuming Cancer Treatment After Ischemic Stroke and Clinical Outcomes.

Neurology·2025

Related Experiment Video

Updated: Jun 7, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.3K

Cancer Therapy-Induced Encephalitis.

Nicolas P Desbaillets1,2, Andreas F Hottinger1,2,3

  • 1Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne University, 1011 Lausanne, Switzerland.

Cancers
|November 9, 2024
PubMed
Summary
This summary is machine-generated.

Cancer therapies, especially immunotherapy, can cause rare but serious encephalitis. Prompt diagnosis and management are crucial for patient outcomes and mitigating neurological toxicities associated with these treatments.

Keywords:
BiTECAR-TICANSadverse eventautoimmunecancercheckpoint inhibitorencephalitisimmunotherapyneurotoxicity

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

17.9K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.3K

Related Experiment Videos

Last Updated: Jun 7, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.3K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

17.9K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.3K

Area of Science:

  • Neuro-oncology
  • Immunology
  • Oncology

Background:

  • Immunotherapy, particularly immune checkpoint inhibitors, is increasingly used in cancer treatment, improving survival rates for metastatic disease.
  • While effective, immunotherapies can cause immune-related adverse events, including neurological toxicities like encephalitis.
  • Encephalitis is a serious concern due to its potential severity and impact on cancer treatment outcomes.

Purpose of the Study:

  • To provide a comprehensive literature review of encephalitis associated with cancer therapies.
  • To highlight optimal diagnostic strategies and management approaches for this condition.
  • To compare immunotherapy-induced encephalitis with that caused by traditional chemotherapy and targeted treatments.

Main Methods:

  • Comprehensive literature search on encephalitis in cancer patients.
  • Analysis of diagnostic criteria and management protocols.
  • Comparative review of etiological agents and treatment responses.

Main Results:

  • Encephalitis is a rare but significant neurological complication of cancer therapies, particularly immunotherapy.
  • Early identification and intervention are key to improving patient prognosis and reducing morbidity.
  • Distinct patterns of encephalitis may be observed with different cancer treatment modalities.

Conclusions:

  • Encephalitis associated with cancer therapies requires specialized diagnostic and management strategies.
  • Understanding the nuances of immunotherapy-induced encephalitis is critical for oncologists and neurologists.
  • Further research is needed to refine treatment protocols and improve long-term outcomes for affected patients.